Video Insights
Video Insights
Advertisement
Brian Shuch, MDRenal Cell Carcinoma Diagnostics | December 20, 2024
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
View More
Brian Shuch, MDRenal Cell Carcinoma Diagnostics | December 19, 2024
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | December 18, 2024
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | December 17, 2024
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
Christopher Cutie, MDNon-Muscle Invasive Urothelial Carcinoma | December 14, 2024
Dr. Christopher Cutie shares his thoughts on the potential of TAR-200 to redefine care for BCG-unresponsive, HR NMIBC.
Christopher Cutie, MDNon-Muscle Invasive Urothelial Carcinoma | December 14, 2024
Dr. Christopher Cutie describes the innovative TAR-200 system and its role in providing sustained intravesical drug delivery.
Akhil Abraham Saji, MDProstate Cancer | December 11, 2024
Drs. Saji and Lebastchi provide an in-depth overview of focal therapy for prostate cancer, including HIFU and IRE therapies.
Regina Barragan-Carrillo, MDAdvanced Renal Cell Carcinoma | December 5, 2024
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
Roger Li, MDMuscle Invasive Urothelial Carcinoma | December 4, 2024
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
Gordon Brown, DOUrothelial Carcinoma | December 3, 2024
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
Gautam Jayram, MDRenal Cell Carcinoma | December 3, 2024
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Gautam Jayram, MDUrothelial Carcinoma | December 3, 2024
Dr. Jayram provides insights into the BCG-unresponsive and BCG-naive bladder cancer space at the LUGPA 2024 Annual Meeting.
Jason Hafron, MDUpper Tract Urothelial Carcinoma | November 22, 2024
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Ana Kiess, MD, PhDmHSPC | November 21, 2024
Ana Kiess, MD, PhD, of Johns Hopkins Medicine, reviews the phase II RAVENS trial on radium-223 with SABR versus SABR alone.
Oliver Sartor, MDRLT | November 21, 2024
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | November 20, 2024
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Sia Daneshmand, MDUrothelial Carcinoma | November 20, 2024
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
Michael Whalen, MDUpper Tract Urothelial Carcinoma | November 6, 2024
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Michael Whalen, MDUpper Tract Urothelial Carcinoma | November 6, 2024
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
Irbaz B. Riaz, MBBS, PhDSPCS 2024 | November 5, 2024
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
Advertisement
Advertisement
Advertisement